Departure of Directors or Certain

2020 Annual Salaries and Stock Option Awards

On December 12, 2019, the Board of Directors
(the Board) of Corvus Pharmaceuticals, Inc. (Corvus or the Company), approved, on recommendation
of the Compensation Committee of the Board, 2020 annual base salaries and stock option awards for the Companys Chief Executive
Officer, Chief Financial Officer and Executive Vice President, Discovery Research. The stock option awards to each of the executive
officers were granted effective as of the close of business on December 12, 2019 with an exercise price equal to the closing price
of the Companys common stock as reported on The Nasdaq Global Market on the date of grant. The awards were made pursuant
to the Companys 2016 Equity Incentive Awa rd Plan and will vest in equal monthly installments over 48 months, subject to
continued service as of each vesting date.

The following table sets forth the 2020 annual
base salary and number of shares underlying the stock option awards for each of the named executive officers and principal financial

Name and Principal Position

2020 Base Salary

Stock Option Award


Richard A. Miller, M.D.



Chief Executive Officer

Leiv Lea



Chief Financial Officer

Joseph J. Buggy, Ph.D.



Executive Vice President, Discovery Research


Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: December 16, 2019


/s/ Leiv Lea

Leiv Lea

Chief Financial Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh